| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8790251 | Urologic Oncology: Seminars and Original Investigations | 2017 | 7 Pages |
Abstract
There are specific immune-related adverse events which are frequently seen by the treating oncologist from checkpoint inhibitors. It is essential to understand the recommended treatment options to minimize toxicity and mortality from this important class of anti-neoplastic therapies.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Andrew W. M.D., David M. M.D., Neeraj M.D., Benjamin L. M.D., Pharm.D.,